Pinealon
Synthetic tripeptide (Glu-Asp-Arg / EDR) developed by the Khavinson group. Brain-penetrant peptide that modulates gene expression in CNS tissues. No published formal pharmacokinetic studies; as an ultrashort tripeptide, plasma half-life is estimated at minutes. Studied for neuroprotection against oxidative stress and cognitive decline.
Projected serum levels — 1 mg, once daily
Maintenance schedule: 1 mg once daily (oral).
Loading schedule: 1.3 mg on day 1, then 1 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~1 days: peak ≈ 0.019 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Peptide
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 7 min
- Common dose
- 1 mg
- Suggested maximum
- 10 mg/day
- Reference dose range
- 0.50–10 mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
Demonstrated Pinealon (EDR) increases cell viability by suppressing reactive oxygen species and activating proliferative processes in neuronal cell cultures under oxidative stress.
-
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
Showed prenatal Pinealon administration protected offspring from hyperhomocysteinemia-induced neurodevelopmental damage, improving cognitive function and cerebellar neuron resistance to oxidative stress.
2 published studies referenced in the app, each with a plain-language summary.